Key facts
- Notable investors include BioGeneration Ventures, Thuja Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Brandaris
- ·The full record, as it builds
Funding rounds
No funding rounds for Brandaris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brandaris
Developer of novel small molecules designed for the treatment of depression and other neuropsychiatric disorders. The company's drugs target the same receptor as psychedelics, using the concept of biased agonism, thus retaining anti-depressive effects without evoking the hallucinogenic ones, enabling healthcare professionals to provide patients a safe and effective treatment option for people.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2020
- Ownership
- Privately Held (backing)
Brandaris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brandaris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brandaris in its N-PORT filings yet. We sweep new filings monthly.